4C Medical's Novel Transcatheter Mitral Valve Technology Awarded Best Technology Parade Presentation at ICI 2017
BROOKLYN PARK, Minn., Dec. 5, 2017 /PRNewswire/ -- 4C Medical Technologies, Inc. (4C Medical), a developer of minimally invasive technologies for structural heart disease, today announced that its medical device for mitral regurgitation (MR) was awarded the Best Technology Parade Presentation at the International Conference for Innovations in Cardiovascular Interventions (ICI) held December 3-5, 2017 in Tel Aviv, Israel.
"We are pleased that the ICI organizers recognized the uniqueness of the 4C valve, our transcatheter mitral valve technology which utilizes a supra-annular, atrial-only fixation approach," said Robert Thatcher, President and CEO of 4C Medical. "This award, from one of the most respected internationally organized innovation conferences, further validates our team's momentum towards the early feasibility study, which is targeted to start by the end of 2018."
Philippe Généreux, MD presented "A Novel Transcatheter MR Technology System (4C valve)" in which he explained how the 4C valve may extend transcatheter mitral valve replacement (TMVR) therapy to patients who would be ineligible for alternative TMVR procedures. Dr. Généreux is Co-Director of the Structural Heart Program at the Gagnon Cardiovascular Institute of Morristown Medical Center (Morristown, NJ) and a practicing Interventional Cardiologist at Hôpital du Sacré-Coeur de Montréal (Montreal, Canada).
"The progress made by the 4C Medical team is astonishing. The engineering team's creative yet practical approach has enabled them to drive the development of the 4C valve at a very rapid pace," said Dr. Généreux. "Because the 4C valve is placed and anchored entirely in the left atrium and does not rely on or interact with the dynamic and irregular anatomy of the mitral annulus and left ventricle, it can be used in a much broader patient population as compared to other TMVR devices. This will lead to quicker patient enrollment in future clinical trials and provide much needed treatment to MR patients."
- Forums
- ASX - By Stock
- Admedus and 4C, the first of many partnerships.
4C Medical's Novel Transcatheter Mitral Valve Technology Awarded...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$12.56 |
Change
-0.740(5.56%) |
Mkt cap ! $265.4M |
Open | High | Low | Value | Volume |
$13.06 | $13.30 | $12.55 | $359.0K | 27.63K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 399 | $12.56 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.78 | 500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 399 | 12.560 |
1 | 722 | 12.550 |
2 | 216 | 12.500 |
1 | 80 | 12.400 |
1 | 50 | 12.350 |
Price($) | Vol. | No. |
---|---|---|
12.780 | 500 | 1 |
12.800 | 712 | 2 |
13.000 | 1793 | 3 |
13.250 | 1000 | 1 |
13.300 | 3 | 1 |
Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |